novartis

Merck’s $6.7B Terns Buy: Cancer Drug Rival?

by

Merck’s $6.7 Billion Terns Pharma Deal: A Strategic Move Against Novartis’s Cancer Dominance In a significant pharmaceutical maneuver, Merck has announced the acquisition of Terns Pharmaceuticals for $6.7 billion. This strategic investment is widely viewed as a proactive step to bolster Merck’s pipeline and mitigate potential revenue losses as its blockbuster cancer drug, Keytruda, faces … Read more

Pluvicto Before Chemo: New Data for Prostate Cancer

by

Pluvicto and the Precision Oncology Revolution: Predicting the Next Wave of Personalized Prostate Cancer Treatment Despite significant advancements, prostate cancer remains a leading cause of cancer death in men. But a paradigm shift is underway, driven by targeted radioligand therapies like Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan). Recent data isn’t just confirming Pluvicto’s efficacy; it’s … Read more

© 2026 Archyworldys. All rights reserved.

For contact, advertising, copyright, issues email: [email protected]